乳腺癌辅助治疗规范的资料解读.pptVIP

MA.17: Trial Design Primary end point: DFS Secondary end points: OS/safety/QOL *n=2575 (efficacy); 2154 (safety) in the FEMARA arm.?n=2582 (efficacy); 2145 (safety) in the placebo arm. Goss et al. N Engl J Med. 2003;349:TBD. Randomization (Disease-free) Tamoxifen Placebo qd? FEMARA (Letrozole) 2.5 mg qd* 5 years early adjuvant 5 years extended adjuvant MA.17 Results: Disease-Free Survival by Treatment Duration (cont’d) Goss et al. N Engl J Med. 2003;349:TBD. 87% 93% Increasing benefit in estimated DFS with treatment duration ATAC EXEM BIG 1.98 (BIG FEMTA) TAMOXIFEN AI PLACEBO ARNO (J)MA